Investor Presentaiton
ENHERTU
DESTINY-Breast04 data
ASCO 2022 Highlights (Plenary Session)
Daiichi-Sankyo
OS in patients with HR+/HER2 low BC
36% reduction in the risk of death versus chemo, mOS of 23.9m
compared to 17.5m with chemo
OS (HR+)
OS in all patients with HR+ or HR-/HER2 low BC
36% reduction in the risk of death versus chemo, mOS of 23.4m
compared to 16.8m with chemo
OS (All patients)
Overall Survival Probability (%)
100
60
10
40
20
20
Hazard ratio: 0.64
95% CI, 0.48-0.86
P = 0.0028
TPC
MOS: 17.5 mo
T-DXd
MOS: 23.9 mo
A 6.4 mo
LI
Overall Survival Probability (%)
100
80
60
40
40
20
Hazard ratio: 0.64
95% CI, 0.49-0.84
P = 0.0010
TPC
MOS: 16.8 mo
A 6.6 mo
T-DXd
MOS: 23.4 mo
0
0
T
T T
T
0 1 2 3 4
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Months
0 1 2 3 4 5 6 7 8
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Months
BC: breast cancer, HR: hormone receptor, mOS: median overall survival, OS: overall survival, T-DXd: trastuzumab deruxtecan, TPC: treatment of physician's choice
19View entire presentation